Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer

Leukemia

Volumn 25, Issue 9, 2011, Pages 1471-1483

  Pike Overzet, K ^a,b   Rodijk, M ^a,b   Ng, Y Y ^a,b   Baert, M R M ^a,b   Lagresle Peyrou, C ^c,d   Schambach, A ^e   Zhang, F ^f   Hoeben, R C ^a   Hacein Bey Abina, S ^c,d   Lankester, A C ^a   Bredius, R G M ^a   Driessen, G J A ^b   Thrasher, A J ^f   Baum, C ^e   Cavazzana Calvo, M ^c,d   Van Dongen, J J M ^b   Staal, F J T ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c INSERM   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Gene therapy; SCID; T lymphocyte

Indexed keywords

ANTIBODY; ANTIGEN; CYTOKINE; IMMUNOGLOBULIN; LENTIVIRUS VECTOR; RAG1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BLOOD; CELL PROLIFERATION; CODON; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE SEQUENCE; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOID ORGAN; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SEVERE COMBINED IMMUNODEFICIENCY; SPLEEN CELL; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS INACTIVATION;

EID: 80052495904     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.106     Document Type: Article

References (48)

1. Notarangelo L, Casanova JL, Conley ME, Chapel H, Fischer A, Puck J et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol 2006; 117: 883-896.
2. Recio MJ, Moreno-Pelayo MA, Kilic SS, Guardo AC, Sanal O, Allende LM et al. Differential biological role of CD3 chains revealed by human immunodeficiencies. J Immunol 2007; 178: 2556-2564. (Pubitemid 46233458)
3. Roberts JL, Lauritsen JP, Cooney M, Parrott RE, Sajaroff EO, Win CM et al. T-B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3zeta subunit of the T-cell antigen receptor complex. Blood 2007; 109: 3198-3206. (Pubitemid 46572504)
4. van der Burg M, van Veelen LR, Verkaik NS, Wiegant WW, Hartwig NG, Barendregt BH et al. A new type of radiosensitive TB-NK+ severe combined immunodeficiency caused by a LIG4 mutation. J Clin Invest 2006; 116: 137-145. (Pubitemid 43121798)
5. van der Burg M, Ijspeert H, Verkaik NS, Turul T, Wiegant WW, Morotomi-Yano K et al. A DNA-PKcs mutation in a radiosensitive T-B-SCID patient inhibits Artemis activation and nonhomologous end-joining. J Clin Invest 2009; 119: 91-98.
6. Corneo B, Moshous D, Gungor T, Wulffraat N, Philippet P, Le Deist FL et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood 2001; 97: 2772-2776.
7. Noordzij JG, de Bruin-Versteeg S, Verkaik NS, Vossen JM, de Groot R, Bernatowska E et al. The immunophenotypic and immunogenotypic B-cell differentiation arrest in bone marrow of RAG-deficient SCID patients corresponds to residual recombination activities of mutated RAG proteins. Blood 2002; 100: 2145-2152. (Pubitemid 35001250)
8. Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D et al. RAG mutations in human B cell-negative SCID. Science 1996; 274: 97-99. (Pubitemid 26332732)
9. Villa A, Sobacchi C, Notarangelo LD, Bozzi F, Abinun M, Abrahamsen TG et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood 2001; 97: 81-88. (Pubitemid 32061245)
10. Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010; 126: 602-610, e1-11.
11. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413. (Pubitemid 34734219)
12. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187. (Pubitemid 40018447)
13. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-1193. (Pubitemid 34984579)
14. Jiang Q, Li WQ, Aiello FB, Klarmann KD, Keller JR, Durum SK. Retroviral transduction of IL-7Ralpha into IL-7Ralpha-/-bone marrow progenitors: correction of lymphoid deficiency and induction of neutrophilia. Gene Ther 2005; 12: 1761-1768. (Pubitemid 41760288)
15. Mostoslavsky G, Fabian AJ, Rooney S, Alt FW, Mulligan RC. Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci USA 2006; 103: 16406-16411. (Pubitemid 44715209)
16. Yates F, Malassis-Seris M, Stockholm D, Bouneaud C, Larousserie F, Noguiez-Hellin P et al. Gene therapy of RAG-2-/-mice: sustained correction of the immunodeficiency. Blood 2002; 100: 3942-3949. (Pubitemid 35396859)
17. Lagresle-Peyrou C, Yates F, Malassis-Seris M, Hue C, Morillon E, Garrigue A et al. Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity. Blood 2006; 107: 63-72. (Pubitemid 43053525)
18. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132-3142.
19. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256. (Pubitemid 36077924)
20. Staal FJ, Pike-Overzet K, Ng YY, van Dongen JJ. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage? Leukemia 2008; 22: 1849-1852.
21. Bukovsky AA, Song JP, Naldini L. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol 1999; 73: 7087-7092. (Pubitemid 29327900)
22. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471. (Pubitemid 28471781)
23. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267. (Pubitemid 26119138)
24. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
25. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194-3198. (Pubitemid 16043003)
26. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880. (Pubitemid 28520853)
27. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300: 1749-1751. (Pubitemid 36712571)
28. Lewinski MK, Yamashita M, Emerman M, Ciuffi A, Marshall H, Crawford G et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog 2006; 2: e60.
29. Lagresle-Peyrou C, Benjelloun F, Hue C, Andre-Schmutz I, Bonhomme D, Forveille M et al. Restoration of human B-cell differentiation into NOD-SCID mice engrafted with gene-corrected CD34+ cells isolated from Artemis or RAG1-deficient patients. Mol Ther 2008; 16: 396-403. (Pubitemid 351168049)
30. Ng YY, Baert MR, Pike-Overzet K, Rodijk M, Brugman MH, Schambach A et al. Correction of B-cell development in Btkdeficient mice using lentiviral vectors with codon-optimized human BTK. Leukemia 2010; 24: 1617-1630.
31. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68: 869-877.
32. Salmon P, Kindler V, Ducrey O, Chapuis B, Zubler RH, Trono D. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 2000; 96: 3392-3398.
33. Zhang F, Frost AR, Blundell MP, Bales O, Antoniou MN, Thrasher AJ. A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther 2010; 18: 1640-1649.
34. Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998; 72: 5085-5092. (Pubitemid 28215689)
35. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892. (Pubitemid 29135675)
36. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 1993; 90: 4319-4323. (Pubitemid 23134218)
37. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317. (Pubitemid 38072572)
38. Fugmann SD, Villey IJ, Ptaszek LM, Schatz DG. Identification of two catalytic residues in RAG1 that define a single active site within the RAG1/RAG2 protein complex. Mol Cell 2000; 5: 97-107. (Pubitemid 30105439)
39. Kane JF. Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr Opin Biotechnol 1995; 6: 494-500.
40. Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16: 718-725. (Pubitemid 351426173)
41. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119: 964-975.
42. Foster H, Sharp PS, Athanasopoulos T, Trollet C, Graham IR, Foster K et al. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol Ther 2008; 16: 1825-1832.
43. Moreno-Carranza B, Gentsch M, Stein S, Schambach A, Santilli G, Rudolf E et al. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther 2009; 16: 111-118.
44. Wayne J, Suh H, Misulovin Z, Sokol KA, Inaba K, Nussenzweig MC. A regulatory role for recombinase activating genes, RAG-1 and RAG-2, in T cell development. Immunity 1994; 1: 95-107.
45. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992; 68: 855-867.
46. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363: 355-364.
47. Sandrin V, Boson B, Salmon P, Gay W, Negre D, Le Grand R et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002; 100: 823-832. (Pubitemid 34832607)
48. Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, Brynza J et al. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 2010; 7: 929-935.